VacZine Analytics  
MarketVIEW: MERS-CoV vaccines

Published: January 2019

MERS-CoV infection a novel coronavirus causes Middle East respiratory syndrome a new disease first identified in Saudi Arabia in 2012. MERS has become significant because it is a virus considered by the WHO and other organisations, e.g. CEPI Coalition for Epidemic Preparedness Innovations to have pandemic potential. At the end of October 2018, 2266 cases of MERS had been reported across 27 countries, but importantly 804 persons had died (case fatality rate = 35.5%). Although transmission is mainly from animals to people, MERS has on occasion been transmitted from human to human, heightening concern. For example, in 2015 MERS infected 185 people starting from an index case that had travelled from the Middle-East.

This MarketVIEW product is a comprehensive Executive Presentation (~100 slides) and MS-Excel forecast model which investigates the commercial potential of a putative MERS-CoV vaccine in all relevant target groups (preventative and emergency scenarios) to 2035. The potential of public (stockpile) and potential private markets are explored. There is comparative analysis of other CEPI based initiatives, e.g. Nipah and Lassa. A detailed case study analysis of Ebola vaccine procurement/deployment also serves as guidance with all assumptions clearly outlined. A thorough review of current disease background/epidemiology and R&D competitive environment are also included. This product is ideally suited to organisations wishing to quantify the MERS-CoV vaccine opportunity.

THIS PRODUCT IS A SUMMARY PRESENTATION (100 slides, .pdf form) + FORECAST MODEL (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV082 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2019 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains